Table 1.
Receptor | Peptide Sequence | Peptide Derivative | Drug | Ref. |
---|---|---|---|---|
Integrin receptor Avβ3 | c(RGDfK) | c(RGDfK)-NHS-PEG-PLA | CA4 | [99] |
c(RGDfK) | c(RGDfK)-SH post liposome modification | CDDP | [100] | |
c(RGDfC) | MBPE-c(RGDfC) post-insertion | DOX | [101] | |
c(RGDf[N-Met]K) | c(RGDf[N-Met]K(Ac-SCH2CO)) | DOX | [102] | |
c(RGDyK) | DSPE-PEG- c(RGDyK) | CDDP | [103] | |
cAbaRGD cAmpRGD |
DSPE-PEG-cAbaRGD DSPE-PEG- cAmpRGD |
DOX DOX |
[104] | |
iRGD | iRGD-HES-SS-C18 NCs | DOX/sorafenib | [105] | |
G-Protein coupled receptor | Octreotide | OCA-DOTA/ OCA-DTPAGlu | Gd-complex | [106] |
Octreotide | (C18)2(AdOO)5OCT | Gd-complex | [107] | |
Octreotide | (C18)2(AdOO)5OCT | CDDP/DOX | [108] | |
Octreotide | OCT-(PTX)-PEG-b-PCL | PTX | [109] | |
Octreotide | Oct-Phe-PEG-SA | DOX | [110] | |
Octreotide | H40-PLA-PEG-OCT | TDP-A | [111] | |
Octreotide | SAMA-TOC post liposome modification | 111In-DTPA | [112] | |
Octreotide | HSPE-PEG4000-OCT | DOX | [113] | |
[Tyr3]-Octreotate | Maleimido-TATE | 64Cu-DOTA | [114] | |
KE108 | KE108 post micelle modification via NHS | TDP-A AB3 |
[115] [116] |
|
[7–14]BN wild-type | (C18)2-L5-[7–14]BN (C18)2-PEG3000-[7–14]BN |
111In-DOTA | [117] | |
[7–14]BN-AA1 analogue | MonY-BN-AA1 | DOX AUL12 DOX |
[118] [119] [120] |
|
CCK8 | (C18)2-L5CCK8 | Gd-DOTA/Gd-DTPA | [121] |